News

Through network biology analysis, Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology

Dale VanderPutten, CEO of Omnia, said: “Vladimir Slepushkin and his team’s breadth of experience in biologics from R&D through clinical development in a wide variety disease targets and

The deal adds a new detection platform to the company’s portfolio of assay technologies and creates options for point-of-need test solutions in select markets. ESE’s optical measurement systems

The suspension of operations at the facility is expected to reduce operating costs by approximately $20m in 2010, with an annualised run-rate of approximately $25m. As a result

Geisinger choose RelayHealth’s RevRunner financial clearance services because it automatically uses multiple means to verify the most current and complete data on a patient’s coverage, copayments, coinsurance and

University Hospitals will leverage Sectra’s new generation PACS with RapidConnect to provide radiology services across a large, distributed group of hospitals and outpatient health and surgery centers. Himanshu

Tom started his career as a Financial Controller in Ecco in 1993. In 1996, Tom joined Danfoss, where he held different financial management roles and lived both in

The agreement allows Jubilant access to DiscoveRx PathHunter and cAMPHunter cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant’s customers. The company

The company also plans to introduce its drug eluting stent (DES) with non-inflammatory properties instead of utilising typical polymeric coatings, which are known to irritate the vessel lining.